Populära just nu
Redeye sees the RPDD and ODD from the FDA as signs that the osteoarthritis programme MIV-711 is movi...
- Clean EBIT SEK 5m vs. ABG SEK 37m - Q2 likely stronger than Q1 - Conference call at 12 CET Clean E...
- Q1: Clean EBITDA NOK -6m - soft compared to our NOK -1m - Targets updated - more achievable - Esti...
Osäkerheten består i det korta, men de strukturella drivkrafterna består Även om affären fortsatte p...
Lägre försäljning men förbättrad lönsamhet Vi förväntar oss att Orexo visar en nettoomsättning för Q...
God tillväxt och fortsatta interna förbättringar i utmanande miljö Bokusgruppen rapporterade en över...
Redeye comments on the change of CEO.
Exel’s Q1 results landed below estimates. Demand shows some signs of improvement, but H1’24 results ...
Dovre Q1 results included a write-down of EUR 5.8m related to a single renewable energy project.
We note another quarter in which the operations have not yet translated into meaningful sales.
Mangold inleder bevakning av greentech-bolaget ChargePanel med rekommendationen Köp.
Redeye has interviewed SSH's Interim CEO, Rami Raulas, regarding the Q1 report.
Redeye sees a Q1 report with sales matching our forecasts, strong net customer intake, and a somewha...
Q1 sales in line with est. at SEK 211m, 8% org. growth EBIT in line, and FCF better than expected at...
Redeye sees a softer Q1 report than expected. Sales, EBIT, and the forward-looking ACV were softer t...